Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.

MLA

Steinman, Lawrence, et al. “Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.” New England Journal of Medicine, vol. 387, no. 8, Aug. 2022, pp. 704–14. EBSCOhost, https://doi.org/10.1056/NEJMoa2201904.

APA

Steinman, L., Fox, E., Hartung, H.-P., Alvarez, E., Peiqing Qian, Wray, S., Robertson, D., Huang, D., Selmaj, K., Wynn, D., Cutter, G., Mok, K., Yanzhi Hsu, Yihuan Xu, Weiss, M. S., Bosco, J. A., Power, S. A., Lee, L., Miskin, H. P., & Cree, B. A. C. (2022). Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. New England Journal of Medicine, 387(8), 704–714. https://doi.org/10.1056/NEJMoa2201904

Chicago

Steinman, Lawrence, Edward Fox, Hans-Peter Hartung, Enrique Alvarez, Peiqing Qian, Sibyl Wray, Derrick Robertson, et al. 2022. “Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.” New England Journal of Medicine 387 (8): 704–14. doi:10.1056/NEJMoa2201904.